Summary: Establishing baseline IGF-1 and growth hormone before using growth hormone-releasing peptides is essential for safe, effective use. Test at four to six weeks to confirm peptides are working, repeat testing every three to six months, and maintain IGF-1 within safe normal ranges. Excessively high IGF-1 offers no additional benefit and carries health risks, so aim for moderate increases within upper-normal range rather than pushing as high as possible.
Two main tests measure growth hormone status: growth hormone itself and IGF-1 (insulin-like growth factor 1). Growth hormone levels fluctuate throughout the day, making them tricky to measure. IGF-1 is more stable, making it a better marker of your average growth hormone levels. This guide explains what these tests mean and how to establish safe baselines before using growth hormone-stimulating peptides.
Understanding Growth Hormone and Its Role
Growth hormone is produced by your pituitary gland—the master gland at the base of your brain. Growth hormone does exactly what its name suggests: it stimulates growth. In children and teenagers, growth hormone makes you taller. In adults, growth hormone helps you build and maintain muscle, maintain bone density, regulate metabolism, and support recovery from exercise.
Growth hormone levels are highest when you’re sleeping deeply, which is why good sleep supports muscle and health. Growth hormone levels also spike after intense exercise. Growth hormone levels naturally decline as you age—this is a normal part of aging.
Normal growth hormone in adults varies widely depending on your age, sex, and test timing. Men typically have growth hormone between 1 and 8 nanograms per milliliter, with higher levels during sleep and after exercise. Women typically have slightly higher levels than men. Growth hormone testing is tricky because it changes minute to minute based on activity, stress, and sleep stage.
IGF-1: The More Useful Growth Hormone Marker
IGF-1 is a hormone your liver produces in response to growth hormone. Your liver constantly produces IGF-1 based on how much growth hormone you’re making. Unlike growth hormone, which fluctuates wildly, IGF-1 remains relatively stable throughout the day. This makes IGF-1 a much better marker of your average growth hormone production.
Normal IGF-1 ranges from 50 to 250 nanograms per milliliter, though normal ranges vary by age and sex. Younger people typically have higher IGF-1 than older people. Your healthcare provider will use age-adjusted ranges to interpret your IGF-1.
Low IGF-1 indicates low growth hormone production. This might mean your pituitary isn’t working well, or it might simply mean your growth hormone hasn’t increased yet from peptides. Building IGF-1 gradually is safer than trying to increase it rapidly.
High IGF-1 indicates high growth hormone production. This is your goal if you’re using growth hormone-releasing peptides—you want to increase growth hormone production. However, very high IGF-1 above the normal range can increase cancer risk and other health problems, so there’s an upper limit to how high you want IGF-1 to go.
Research shows that targeting upper-normal IGF-1 range is safe as long as you don’t exceed the upper limit. Gradual increases within normal range appear safer than trying to push IGF-1 excessively high.
Establishing Your Baseline Before Starting Peptides
Get IGF-1 and growth hormone tested before starting any growth hormone-releasing peptides. This baseline establishes where you’re starting, allowing you to measure whether peptides are actually working.
Your baseline IGF-1 matters because it affects your dosing strategy. If you start with low IGF-1, peptides might be more effective at increasing it. If you start with high-normal IGF-1, you might need lower peptide doses to avoid pushing IGF-1 too high.
Testing growth hormone alongside IGF-1 gives more complete information. A growth hormone test after you’ve rested (early morning) and perhaps after a brief session of moderate exercise gives a snapshot of your production capacity.
Make sure testing is done consistently—same time of day, same conditions—so you can compare baseline to future tests fairly. Morning testing on a day when you’re well-rested is ideal.
Monitoring IGF-1 During Peptide Use
After starting growth hormone-releasing peptides, check IGF-1 at four to six weeks. This early check shows whether peptides are working. If peptides are effective, IGF-1 should be rising. If it’s unchanged, peptides might not be working or your dose might need adjustment.
Check IGF-1 again at eight to twelve weeks. By this time, if peptides are working, IGF-1 should be significantly elevated. Most people experience 20 to 50 percent increases in IGF-1 with effective growth hormone-releasing peptides.
After reaching a stable dose, check IGF-1 every three to six months. Stable, consistent IGF-1 indicates consistent growth hormone production. Gradual IGF-1 increases over many months might indicate your body is adapting to peptides differently.
Watch for IGF-1 rising above your target range. If IGF-1 exceeds the upper normal limit, discuss dose reduction with your healthcare provider. Excessively high IGF-1 isn’t beneficial and carries health risks.
Interpreting Changes in Your IGF-1
An IGF-1 increase of 25 to 50 nanograms per milliliter is typical when peptides are working well. This level of increase usually produces noticeable benefits in muscle development, recovery, and energy without pushing into dangerously high ranges.
An IGF-1 increase of 100 nanograms per milliliter or more suggests high-dose peptide response. This might produce excellent results or it might be pushing too high. Discuss with your healthcare provider whether to reduce peptide doses.
An IGF-1 increase of less than 10 nanograms per milliliter after six weeks suggests peptides aren’t working well for you. Either your dose is too low, peptides aren’t compatible with your physiology, or you need a different peptide.
An IGF-1 that increases initially then plateaus or decreases suggests your body is adapting to peptides. You might need dose adjustments or might benefit from cycling peptides (taking them for a period, then taking a break).
Growth Hormone and IGF-1 Safety Considerations
While moderate IGF-1 increases support muscle and bone health, very high IGF-1 is associated with increased cancer risk. This is why maintaining IGF-1 within normal range is important—you want the benefits of increased growth hormone without the risks of excessive elevation.
Some research suggests that keeping IGF-1 in the upper-normal range rather than very high provides benefits while minimizing risks. Avoid trying to push IGF-1 excessively high, as this offers no additional benefit and increases health risks.
If you have a personal or family history of certain cancers, discuss growth hormone-releasing peptides with your healthcare provider before starting. Your individual cancer risk might affect whether peptides are appropriate for you.
Some people experience joint pain, carpal tunnel symptoms, or water retention as IGF-1 increases. These side effects often resolve with dose adjustment. Discuss bothersome symptoms with your healthcare provider.
Special Situations and Age Considerations
Your baseline age affects IGF-1 interpretation. Younger people have naturally higher IGF-1, so a 150 IGF-1 is normal for a 25-year-old but elevated for a 65-year-old. Age-adjusted normal ranges matter.
If you’re over 50, growth hormone-releasing peptides can provide benefits, but monitoring becomes especially important. Discuss with your healthcare provider whether peptides are appropriate for your age and whether your cancer risk changes peptide recommendations.
If you have metabolic conditions like prediabetes or diabetes, growth hormone might affect your blood sugar. Monitor glucose alongside IGF-1 when using growth hormone-releasing peptides. Some people experience slight glucose increases with higher growth hormone.
If you have pituitary disease or previous head injury, discuss growth hormone-releasing peptides with an endocrinologist before starting. Your pituitary function affects how well peptides work.
